ClinicalTrials.gg
CompletedNCT00313300Updated Dec 30, 2015Results posted

Safety Study of Apixaban in Recent Acute Coronary Syndrome

A Phase 2 interventional study of Apixaban and Apixaban in Acute Coronary Syndrome (ACS), sponsored by Bristol-Myers Squibb. Completed at 151 sites in 14 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2015-12-30.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,741
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Enrollment
39th of 186
1,741 · median 150
Started
2006
with 17 others
Phase 2
29 of 265
2 open now
Registered
15th of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 39th largest by enrollment of the 186 interventional ones that give a count, is one of 18 that started in 2006, is one of 29 in phase 2, and was the 15th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.

03

Conditions studied

  • Acute Coronary Syndrome (ACS)
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Recent (\< = 7 days) Acute Coronary Syndrome (ACS).
  • Clinically stable on optimal treatment

Key Exclusion Criteria:

  • High bleeding risk.
  • Ongoing anticoagulant use.
  • Need for chronic (>3 months) daily nonsteroidal anti-inflammatory drug (NSAID) or chronic high dose acetylsalicylic acid (ASA) use (>325 mg/day
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,741 participants (actual)

Study arms

  • Active comparator
    A1

    Drug: Apixaban

  • Experimental
    A2

    Drug: Apixaban

  • Placebo comparator
    A3

    Drug: Placebo

  • Experimental
    A4

    Drug: Apixaban

Interventions

  • Tablets, Oral, 2.5 mg, twice daily, 26 weeks

  • Tablets, Oral, 10 mg, once daily, 26 weeks

  • DrugPlacebo

    Tablets, Oral, 0, twice daily, 26 weeks

  • Tablets, Oral 10 mg, twice daily, 26 weeks

06

What researchers measure

Primary outcomes

  1. Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses

    Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups.

    Time frame: From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study

Secondary outcomes

  1. Number of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants

    Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B.

    Time frame: Randomization to 182 days after randomization (183 days)

  2. Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses

    Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B.

    Time frame: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study

  3. Number of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants

    Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B

    Time frame: Day of randomization to 182 days after day of randomization (183 days)

  4. Event Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses

    Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%).

    Time frame: from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study

  5. Number of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B

    Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure.

    Time frame: Day of randomization and ends on high dose termination date, 1-Oct-2007

  6. Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B

    Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group).

    Time frame: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007

  7. Event Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B

    Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group).

    Time frame: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007

  8. Number of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B

    Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure.

    Time frame: Day of randomization up to high dose termination, 1-Oct-2007

  9. Event Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B

    Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%).

    Time frame: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007

07

Results

Posted Oct 15, 2015

Participant flow

Randomized in Phase A (26 Weeks)
Participant flow — Randomized in Phase A (26 Weeks)
MilestonePlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Started18417918400
Completed13014014900
Not completed54393500
Withdrew: Adverse event19141700
Withdrew: Withdrawal by subject20121300
Withdrew: Death34000
Withdrew: Lost to follow-up44200
Withdrew: Poor/non-compliance32100
Withdrew: No longer meets criteria43200
Withdrew: Administrative reason (arm terminated)10000
Randomized in Phase B (26 Weeks)
Participant flow — Randomized in Phase B (26 Weeks)
MilestonePlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Started427138134248221
Start of phase b to high dose terminated368120110248221
Completed333105941513
Not completed943340233208
Withdrew: Adverse event349122319
Withdrew: Withdrawal by subject3514191519
Withdrew: Death53101
Withdrew: Lost to follow-up52323
Withdrew: Poor/non-compliance31300
Withdrew: No longer meets criteria93202
Withdrew: Administrative reason by sponsor210193164
Withdrew: Non-specified10000
Follow-Up(30days)-Randomized Phase A
Participant flow — Follow-Up(30days)-Randomized Phase A
MilestonePlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Started16316217400
Completed15815617200
Not completed56200
Withdrew: Withdrawal by subject55200
Withdrew: Death01000
Follow-Up(30days)-Randomized Phase B
Participant flow — Follow-Up(30days)-Randomized Phase B
MilestonePlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Started383123119222201
Completed380123117217199
Not completed30252
Withdrew: Withdrawal by subject10211
Withdrew: Death10000
Withdrew: Lost to follow-up00021
Withdrew: Missing end of study status10020

Outcome measures

PrimaryEvent Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses

Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups.

Time frame:
From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study
Reported as:
Number · percentage of participants
Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses
percentage of participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QD
Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses3.0 (1.8 to 4.7)5.7 (3.4 to 8.9)7.9 (5.2 to 11.5)
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Adjusted rate difference: 2.2 · 95% CI -1.0 to 5.4adjusted difference of event rates takes into consideration stratification factors.
  • Placebo vs Apixaban 10mg QD · Adjusted rate difference: 3.8 · 95% CI 0.4 to 7.3adjusted difference of event rates takes into consideration stratification factors.
SecondaryNumber of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants

Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B.

Time frame:
Randomization to 182 days after randomization (183 days)
Reported as:
Number · participants
Number of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants
participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QD
Number of Participants With a Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants532419
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Hazard ratio (hr): 0.73 · 95% CI 0.44 to 1.19
  • Placebo vs Apixaban 10mg QD · Hazard ratio (hr): 0.61 · 95% CI 0.35 to 1.04
SecondaryEvent Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses

Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B.

Time frame:
first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study
Reported as:
Number · percentage of participants
Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses
percentage of participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QD
Event Rate for Adjudicated All Bleeding Events During the Treatment Period - Treated Participants With Placebo or Apixaban Low Doses10.5 (8.2 to 13.3)20.6 (16.3 to 25.5)22.5 (18.0 to 27.6)
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Adjusted rate difference: 6.6 · 95% CI 1.8 to 11.3adjusted difference of event rates takes into consideration stratification factors.
  • Placebo vs Apixaban 10mg QD · Adjusted rate difference: 10.0 · 95% CI 4.8 to 15.2adjusted difference of event rates takes into consideration stratification factors.
SecondaryNumber of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants

Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B

Time frame:
Day of randomization to 182 days after day of randomization (183 days)
Reported as:
Number · participants
Number of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants
participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QD
Number of Participants With a Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, and Non-Hemorrhagic Stroke During the Intended Treatment Period - Randomized Participants542420
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Hazard ratio (hr): 0.71 · 95% CI 0.44 to 1.17
  • Placebo vs Apixaban 10mg QD · Hazard ratio (hr): 0.63 · 95% CI 0.37 to 1.07
SecondaryEvent Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses

Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%).

Time frame:
from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study
Reported as:
Number · percentage of participants
Event Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses
percentage of participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QD
Event Rate of Confirmed Adjudicated Major Bleeding During the Treatment Period- Treated Participants With Placebo or Apixaban Low Doses0.8 (0.3 to 1.9)1.6 (0.5 to 3.7)1.9 (0.7 to 4.1)
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Adjusted rate difference: 0.3 · 95% CI -1.3 to 2.0adjusted difference of event rates takes into consideration stratification factors.
  • Placebo vs Apixaban 10mg QD · Adjusted rate difference: 0.8 · 95% CI -1.1 to 2.7adjusted difference of event rates takes into consideration stratification factors.
SecondaryNumber of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B

Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure.

Time frame:
Day of randomization and ends on high dose termination date, 1-Oct-2007
Reported as:
Number · participants
Number of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B
participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Number of Participants With Composite of Adjudicated All-Cause Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B166487
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Hazard ratio (hr): 1.13 · 95% CI 0.44 to 2.88
  • Placebo vs Apixaban 10mg QD · Hazard ratio (hr): 0.86 · 95% CI 0.29 to 2.57
  • Placebo vs Apixaban 10mg BID · Hazard ratio (hr): 0.71 · 95% CI 0.30 to 1.66
  • Placebo vs Apixaban 20 mg QD · Hazard ratio (hr): 0.72 · 95% CI 0.30 to 1.74
SecondaryEvent Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B

Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group).

Time frame:
From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
Reported as:
Number · percentage of participants
Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B
percentage of participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Phase B Adjusted Treatment Period- Treated Participants Randomized in Phase B0.8 (0.2 to 2.4)5.0 (1.9 to 10.7)5.6 (2.1 to 11.7)7.8 (4.8 to 11.9)7.3 (4.3 to 11.6)
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Adjusted rate difference: 4.0 · 95% CI 0.0 to 8.1
  • Placebo vs Apixaban 10mg QD · Adjusted rate difference: 4.7 · 95% CI 0.0 to 9.3
  • Placebo vs Apixaban 10mg BID · Adjusted rate difference: 7.0 · 95% CI 3.4 to 10.5
  • Placebo vs Apixaban 20 mg QD · Adjusted rate difference: 4.7 · 95% CI 1.4 to 8.0
SecondaryEvent Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B

Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group).

Time frame:
From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
Reported as:
Number · percentage of participants
Event Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B
percentage of participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Event Rate for Adjudicated All Bleeding Events During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B6.1 (3.8 to 9.1)15.1 (9.2 to 22.8)17.6 (10.9 to 26.1)24.2 (18.9 to 30.1)23.9 (18.4 to 30.1)
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Adjusted rate difference: 8.3 · 95% CI 1.8 to 14.9
  • Placebo vs Apixaban 10mg QD · Adjusted rate difference: 10.9 · 95% CI 3.4 to 18.4
  • Placebo vs Apixaban 10mg BID · Adjusted rate difference: 17.4 · 95% CI 11.6 to 23.2
  • Placebo vs Apixaban 20 mg QD · Adjusted rate difference: 10.4 · 95% CI 5.6 to 15.1
SecondaryNumber of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B

Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure.

Time frame:
Day of randomization up to high dose termination, 1-Oct-2007
Reported as:
Number · participants
Number of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B
participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Number of Participants With Composite of Adjudicated Cardiovascular Death, Non-Fatal Myocardial Infarction, Severe Recurrent Ischemia, Non-Hemorrhagic Stroke During the Phase B Adjusted Intended Treatment Period - Participants Randomized in Phase B166487
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Cox proportional hazard: 1.13 · 95% CI 0.44 to 2.88
  • Placebo vs Apixaban 10mg QD · Cox proportional hazard: 0.86 · 95% CI 0.29 to 2.57
  • Placebo vs Apixaban 10mg BID · Cox proportional hazard: 0.71 · 95% CI 0.30 to 1.66
  • Placebo vs Apixaban 20 mg QD · Cox proportional hazard: 0.72 · 95% CI 0.30 to 1.74
SecondaryEvent Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B

Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%).

Time frame:
From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
Reported as:
Number · percentage of participants
Event Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B
percentage of participantsPlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QD
Event Rate of Confirmed Adjudicated Major Bleeding During the Phase B Adjusted Treatment Period - Treated Participants Randomized in Phase B0.0 (0.0 to 1.0)0.8 (0.0 to 4.6)0.0 (0.0 to 3.4)2.9 (1.2 to 5.8)4.1 (1.9 to 7.7)
Statistical analysis
  • Placebo vs Apixaban 2.5mg BID · Adjusted rate difference: 0.8 · 95% CI -0.9 to 2.6
  • Placebo vs Apixaban 10mg BID · Adjusted rate difference: 2.9 · 95% CI 0.6 to 5.1
  • Placebo vs Apixaban 20 mg QD · Adjusted rate difference: 4.1 · 95% CI 1.3 to 6.9

Adverse events

Collected over Day 1 up to 30 days post last dose of study drug, up to approximately 2 years: A+B treatment groups. March 2007 up to 30 days post last dose in October 2007 (termination of high doses), are presented in Phase B Treatment groups.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase A+B Apixaban 10mg QD—72/315 (22.9%)122/315 (38.7%)
Phase A+B Apixaban 2.5mg BID—73/315 (23.2%)101/315 (32.1%)
Phase A+B Placebo—125/599 (20.9%)175/599 (29.2%)
Phase B Apixaban 10mg BID—55/244 (22.5%)84/244 (34.4%)
Phase B Apixaban 10mg QD—22/108 (20.4%)30/108 (27.8%)
Phase B Apixaban 20mg QD—36/218 (16.5%)67/218 (30.7%)
Phase B Apixaban 2.5mg BID—19/119 (16%)22/119 (18.5%)
Phase B Placebo—56/362 (15.5%)80/362 (22.1%)
Most frequent serious events
Showing 10 of 176
Most frequent serious events
EventPhase A+B Apixaban 10mg QDPhase A+B Apixaban 2.5mg BIDPhase A+B PlaceboPhase B Apixaban 10mg BIDPhase B Apixaban 10mg QDPhase B Apixaban 20mg QDPhase B Apixaban 2.5mg BIDPhase B Placebo
Myocardial infarctionCardiac disorders11/3158/31524/5993/2443/1081/2181/11912/362
Chest painGeneral disorders7/3156/31513/5997/2442/1086/2181/1198/362
Non-cardiac chest painGeneral disorders6/3152/3154/5995/2443/1081/2180/1192/362
IschaemiaVascular disorders8/3154/31512/5994/2442/1086/2181/1195/362
Angina pectorisCardiac disorders6/3158/31511/5995/2441/1083/2182/1194/362
Angina unstableCardiac disorders5/3156/31514/5995/2442/1083/2180/1196/362
PyrexiaGeneral disorders0/3152/3150/5990/2440/1080/2182/1190/362
Acute myocardial infarctionCardiac disorders1/3154/3154/5993/2440/1081/2181/1192/362
Atrial fibrillationCardiac disorders4/3153/3153/5990/2441/1080/2181/1192/362
Gastrointestinal haemorrhageGastrointestinal disorders0/3151/3151/5993/2440/1080/2181/1190/362
Most frequent other events
Most frequent other events
EventPhase A+B Apixaban 10mg QDPhase A+B Apixaban 2.5mg BIDPhase A+B PlaceboPhase B Apixaban 10mg BIDPhase B Apixaban 10mg QDPhase B Apixaban 20mg QDPhase B Apixaban 2.5mg BIDPhase B Placebo
EpistaxisRespiratory, thoracic and mediastinal disorders24/31518/31518/59916/2445/10825/2184/1192/362
Chest painGeneral disorders27/31521/31552/59919/2449/10814/2184/11924/362
ContusionInjury, poisoning and procedural complications26/31520/31520/59912/2444/10810/2184/11910/362
HeadacheNervous system disorders25/31517/31530/59915/2442/1086/2180/11912/362
FatigueGeneral disorders8/31513/31526/59916/2441/1086/2184/11914/362
Gingival bleedingGastrointestinal disorders11/31510/3159/59915/2442/1088/2184/1194/362
Angina pectorisCardiac disorders19/31518/31531/59910/2445/10811/2183/11912/362
DizzinessNervous system disorders18/31515/31535/59910/2444/1089/2183/11916/362
DyspnoeaRespiratory, thoracic and mediastinal disorders16/31513/31520/5993/2446/1084/2184/11910/362
HaematomaVascular disorders16/31511/31510/5999/2445/1089/2184/1195/362

Baseline characteristics

All randomized participants were summarized.

Age, Continuous
Age, Continuous(years)PlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QDTotal
Mean60.5 ± 11.2561.1 ± 11.6460.7 ± 11.3560.3 ± 11.0060.9 ± 11.9560.7 ± 11.38
Age, Customized
Age, Customized(participants)PlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QDTotal
Less than (<) 65 years3741871971651321055
Greater than, equal to 65 and < 75 years17085825357447
Greater than (>) 75 years6745393032213
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QDTotal
Female15775864550413
Male4542422322031711302
Region of Enrollment
Region of Enrollment(participants)PlaceboApixaban 2.5mg BIDApixaban 10mg QDApixaban 10mg BIDApixaban 20 mg QDTotal
Russian Federation15693825952442
United States6940442414191
United Kingdom15795541
Spain361116171999
Canada8147442621219
Austria4224214
Sweden4221241212111
Belgium20119101262
Poland6121193431166
Denmark1614155454
Israel5529322621163
France219881056
Germany341214171895
Italy100102
08

Study locations

151 sites
  • Scottsdale Cardiovasular Research Institute
    Scottsdale, Arizona 85251, United States
  • Los Angeles County & University Of Southern Ca. Medical Cen.
    Los Angeles, California 90033, United States
  • Radiant Research,Santa Rosa
    Santa Rosa, California 95405, United States
  • South Denver Cardiology Associates
    Littleton, Colorado 80120, United States
  • Watson Clinic Center For Research
    Lakeland, Florida 33805, United States
  • Heart & Vasc Inst Of Fl
    Safety Harbor, Florida 34695, United States
  • Indian River Medical Center
    Vero Beach, Florida 32960, United States
  • Cardiac Disease Specialists, P.C.
    Atlanta, Georgia 30309, United States
  • Georgia Heart Specialists
    Covington, Georgia 30014, United States
  • Heartcare Midwest
    Peoria, Illinois 61614, United States
  • The Care Group, Llc.
    Indianapolis, Indiana 46290, United States
  • Iowa Heart Center
    Des Moines, Iowa 50314, United States
  • University Of Kentucky
    Lexington, Kentucky 40536, United States
  • William Beaumont Hospital-Troy
    Troy, Michigan 48085, United States
  • New York Cardiovascular Associates
    New York, New York 10001, United States
  • Unc Hospitals, Department Of Medicine
    Chapel Hill, North Carolina 27599, United States
  • Dumc
    Durham, North Carolina 27705, United States
  • Carolina Heart Specialists
    Gastonia, North Carolina 28054, United States
  • Piedmont Cardiology Associates
    Hickory, North Carolina 28602, United States
  • Wake Forest Univ Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Midwest Cardiology Research Foundation
    Columbus, Ohio 43214, United States
  • The Dayton Heart Center
    Dayton, Ohio 45414, United States
  • Oklahoma Cardiovascular Research Group
    Oklahoma City, Oklahoma 73120, United States
  • Geisinger Clinic - Cardiology
    Danville, Pennsylvania 17822, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Cardiovascular Associates, P.C
    Kingsport, Tennessee 37660, United States
  • University Of Texas Medical School - San Antonio
    San Antonio, Texas 78229, United States
  • Tyler Cardiovascular Consultants
    Tyler, Texas 75701, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Local Institution
    Feldkirch, 6800, Austria
  • Local Institution
    Wien, 1090, Austria
  • Local Institution
    Wien, 1160, Austria
  • Local Institution
    Huy, Luik 4500, Belgium
  • Local Institution
    Aalst, 9300, Belgium
  • Local Institution
    Antwerpen, 2020, Belgium
  • Local Institution
    Brasschaat, 2930, Belgium
  • Local Institution
    Brugge, 8000, Belgium
  • Local Institution
    Brussels, 1090, Belgium
  • Local Institution
    Genk, 3600, Belgium
  • Local Institution
    Edmonton, Alberta T5H 3V9, Canada
  • Local Institution
    Edmonton, Alberta T6G 2B7, Canada
  • Local Institution
    Edmonton, Alberta T6K 4C1, Canada
  • Local Institution
    Victoria, British Columbia V8R 4R2, Canada
  • Local Institution
    St. John'S, Newfoundland and Labrador A1B 3V6, Canada
  • Local Institution
    Belleville, Ontario K8N1E6, Canada
  • Local Institution
    Chatham, Ontario N7L 1B9, Canada
  • Local Institution
    Hamilton, Ontario L8L 2X2, Canada
  • Local Institution
    London, Ontario N6A 5A5, Canada
  • Local Institution
    Oshawa, Ontario L1H 1B9, Canada
  • Local Institution
    Montreal, Quebec H1T 1C8, Canada
  • Local Institution
    Montreal, Quebec H1T 2M4, Canada
  • Local Institution
    Montreal, Quebec H2X 3J4, Canada
  • Local Institution
    St. Charles-Borromee, Quebec J6E 6J2, Canada
  • Local Institution
    Terrebonne, Quebec J6V 2H2, Canada
  • Local Institution
    Arhus C, 8000, Denmark
  • Local Institution
    Copenhagen, 2100, Denmark
  • Local Institution
    Esbjerg, 6700, Denmark
  • Local Institution
    Frederiksberg, 2000, Denmark
  • Local Institution
    Glostrup, 2600, Denmark
  • Local Institution
    Hellerup, 2900, Denmark
  • Local Institution
    Herning, 7400, Denmark
  • Local Institution
    Randers, DK-8900, Denmark
  • Local Institution
    Amiens Cedex 1, 80054, France
  • Local Institution
    Cholet, 49300, France
  • Local Institution
    Dijon, 21079, France
  • Local Institution
    Nantes Cedex 01, 44093, France
  • Local Institution
    Paris Cedex 13, 75651, France
  • Local Institution
    Pessac Cedex, 33604, France
  • Local Institution
    Roubaix Cedex 1, 59056, France
  • Local Institution
    Toulouse, 31403, France
  • Local Institution
    Berlin, 12351, Germany
  • Local Institution
    Berlin, 12559, Germany
  • Local Institution
    Duren, 52351, Germany
  • Local Institution
    Halle / Saale, 06120, Germany
  • Local Institution
    Hannover, 30625, Germany
  • Local Institution
    Krefeld, 47805, Germany
  • Local Institution
    Langen, 63225, Germany
  • Local Institution
    Ludwigshafen, 67063, Germany
  • Local Institution
    Witten, 58455, Germany
  • Local Institution
    Afula, 18101, Israel
  • Local Institution
    Hadera, 38100, Israel
  • Local Institution
    Haifa, 31096, Israel
  • Local Institution
    Haifa, 34362, Israel
  • Local Institution
    Jerusalem, 91031, Israel
  • Local Institution
    Jerusalem, 91120, Israel
  • Local Institution
    Jerusalem, 91240, Israel
  • Local Institution
    Kfar-Saba, 44281, Israel
  • Local Institution
    Nazareth, 16100, Israel
  • Local Institution
    Petach Tikva, 49100, Israel
  • Local Institution
    Rehovot, 76100, Israel
  • Local Institution
    Safed, 13100, Israel
  • Local Institution
    Tel Aviv, 64239, Israel
  • Local Institution
    Roma, 00168, Italy
  • Local Institution
    Bialystok, 15-276, Poland
  • Local Institution
    Bydgoszcz, 85-094, Poland
  • Local Institution
    Bydgoszcz, 85-168, Poland
  • Local Institution
    Bydgoszcz, 85-826, Poland
  • Local Institution
    Cracow, 31-202, Poland
  • Local Institution
    Gdansk, 80-952, Poland

Showing the first 100 of 151 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • APPRAISE Steering Committee and Investigators; Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. Epub 2009 May 26. PubMed 19470889 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 7 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2006
First posted
Apr 12, 2006
Start
May 2006
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Oct 15, 2015
Last update
Dec 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00313300
Responsible party
Sponsor
First posted
Apr 12, 2006
Start date
May 2006
Primary completion
May 2008
Completion
May 2008
Results posted
Oct 15, 2015
Last update
Dec 30, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion